Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPD704 in healthy Chinese adults
NCT07301203Phase 1Recruiting
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CPD704 in idiopathic pulmonary fibrosis (IPF), sponsored by Beijing Tide Pharmaceutical Co., Ltd. Primary endpoint: Safety outcomes at 14 days. Started Oct 2025; status: recruiting.
02
Drugs
CPD704
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07301203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301203.